Effects of Jianpi herbal suppository on hemorheology and CD62p in patients with ulcerative colitis  by Han, Jie et al.
TOPIC
JTCM |www. journaltcm. com April 15, 2013 |Volume 34 | Issue 2 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2014 April 15; 34(2): 155-158
info@journaltcm.com ISSN 0255-2922
© 2014 JTCM. All rights reserved.
CLINICAL STUDY
Effects of Jianpi herbal suppository on hemorheology and CD62p in
patients with ulcerative colitis
Jie Han, JianWang, Jiaoying HWang
aa
Jie Han, Department of Digestology, the First Affiliated Hos-
pital of Henan University of Chinese Medicine, Zhengzhou
450000, China
JianWang, Queensland Herbarium, Department of Environ-
ment and Resource Management, Brisbane Botanic Gar-
dens, Queensland 4066, Australia
Jiaoying H Wang, School of Pharmacy, University of
Queensland, Queensland 4072, Australia
Correspondence to: Prof. Jie Han, Department of Digestol-
ogy, the First Affiliated Hospital of Henan University of Chi-
nese Medicine, Zhengzhou 450000, China. han_jie1974@
163.com
Telephone: +86-13653868892
Accepted: September 3, 2013
Abstract
OBJECTIVE: To compare the effects of a Chinese
herbal suppository (Jianpi suppository) and West-
ern Medicine (mesalazine) on hemorheology and
CD62p in patients with ulcerative colitis (UC).
METHODS: In a randomized trial, 120 mild to mod-
erate UC patients were randomly divided into two
equal groups. The Jianpi suppository group used
Chinese herbal suppository rectally, while the me-
salazine group was treated with mesalazine tablets
orally. Two 15-day courses of treatment were car-
ried out in both groups. Changes in the hemorheol-
ogy and CD62p indices in patients were observed.
RESULTS: The hemorheology and CD62p indices in
the Jianpi suppository group decreased significant-
ly more than those of the mesalazine group.
CONCLUSION: Jianpi suppository is effective in im-
proving the hypercoagulability of UC patients, and
therefore may be worth using in clinical practice.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Ulcerative colitis (UC) is a major form of inflammato-
ry bowel disease that affects the digestive system.1 UC
causes ulcers and inflammation of the inner lining of
the colon, leading to abdominal pain, diarrhea with
bloody and mucousy stools, rectal bleeding, and possi-
ble weight loss.2 UC is a common disease worldwide,
and there is a risk for developing colorectal cancer in
prolonged UC cases.3-5 Although its pathogenesis is still
unclear, some reports indicate that it is associated with
the hypercoagulable state of UC patients.6-8 Patients
with hypercoagulability have a risk of developing heart
attacks if left untreated so more research is being con-
ducted. Hypercoagulability is usually assessed by
hemorheology and platelet glycoprotein CD62p indi-
ces.9,10 Hemorheology relates to blood pressure, flow,
volumes, and resistances in blood vessels. CD62p is a
protein in the adhesion molecule family and is one of
the components activated by platelets and expressed by
endothelial cells. It is a sign of activation of these cells,
mediated by the attachment of neutrophils and mono-
cytes on activated platelets and endothelial cells.
To date, there are no medical cures for UC. Because
UC usually has a relapsing-remitting characteristic that
manifests as increased inflammatory activity and symp-
toms,11 medical treatments usually target controlling in-
testinal inflammation.12 Mesalazine (5-aminosalicylic
acid or 5-ASA) is an anti-inflammatory drug and has
highly effective, relatively safe and well-tolerated effects
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in the induction and maintenance of remission of mild
to moderate UC.13 Therefore, it has been used as the
first-line therapy in UC patients for the past 30 years.14
Mesalazine has the best safety profile for the induction
and maintenance of both clinical and endoscopic remis-
sion in mild to moderate UC. However, its side effects,
including headache, nausea, dyspepsia, flatulence, and
diarrhea are common. Moreover, because UC is typical-
ly a lifelong disease, some patients can develop drug re-
sistance.
In UC patients, erosion is mostly on the left side of the
colon (including the rectum and sigmoid colon). Chi-
nese herbal suppository has the advantage of acting di-
rectly on these erosions. Suppositories have been used
for UC patients more commonly in the last 10-15
years,15,16 with satisfactory effects.17-20 Our new Chinese
herbal suppository, Jianpi suppository, received a na-
tional patent in 2012. In clinical applications, it is ef-
fective in significantly improving the hypercoagulable
state of mild to moderate UC patients. Its cost is also
much lower, about one third or less, than using mesala-
zine. The aim of this study is to compare the effects of
Jianpi suppository with that of mesalazine on hemorhe-
ology and CD62p in UC patients to provide a theoreti-
cal basis for clinical practice.
METHODS
Clinical data
All 120 patients with a confirmed diagnosis of mild to
moderate UC were in- and out-patients of the First Af-
filiated Hospital of Henan University of Chinese Medi-
cine from January 2006 to October 2012. In a random-
ized fashion (using table of random number), patients
were equally divided into two groups: treatment group
using Jianpi suppository and the control group using
mesalazine. In treatment group, there were 32 male pa-
tients, 28 female patients. The mean age was 33±7, the
mean disease course was 9.41 ± 2.35; and in control
group, there were 34 male patients, 26 female patients.
The mean age was 34±6, the mean disease course was
8.79 ± 3.04; there was no obvious difference between
the two groups in sex, age, and disease course (P>
0.05) . All patients had colon lesions in either the rec-
tum or sigmoid colon. The research was approved by
Ethics Committee of the First Affiliated Hospital of
Henan University of Chinese Medicine. Written in-
formed consent was signed by all patients before the
study.
Diagnostic standards
For Western Medicine, diagnosis was based on clinical
symptoms and the endoscopic, histopathological, and
radiologic findings that satisfy the internationally ac-
cepted Lennard-Jones criteria.21 For Chinese medicine,
diagnosis was based on the clinical research guidelines
of new and Traditional Chinese Medicine.22 Patients
were included in the trial if they were 18-65 years old,
and met the diagnostic standards of Western and Tradi-
tional Chinese Medicine. Patients were excluded if
they had: infectious colitis or lesions above the rectum
or sigmoid colon.
Treatment
In the Jianpi suppository group, Jianpi suppository was
given rectally. The ingredients of the suppository were:
Huangqi (Radix Astragali Mongolici), Dangshen (Radix
Codonopsis), Baizhu (Rhizoma Atractylodis Macrocepha-
lae), Fuling (Poria), Machixian (Herba Portulacae Olera-
ceae), and Diyu (Radix Sanguisorbae). The suppository
was produced by the pharmaceutical factory of the
First Affiliated Hospital of Henan University of Chi-
nese Medicine (Henan, China). Two suppositories
were put into the anus each day in the evening before
bed, with 15 days as one course of treatment.
In the mesalazine group, mesalazine was administered
for orally. The dosage was 0.25 g (Jiamusi Luling Phar-
maceutical Co., Ltd., Jiamusi, China). Batch number:
H 19980148). Four tablets were taken each time for a
total dose of 1 g, three times a day, with 15 days as one
course of treatment. Both groups were observed for
two courses of treatment.
Observation indices
The pathogenesis of UC is associated with an obvious
increase in red blood cell (RBC) aggregation, rigidity
index, and erythrocyte sedimentation rate. The sedi-
mentation equation of K value is also increased to vary-
ing degrees. The four indices tested were: blood sedi-
mentation rate, K value, gather index, and rigidity in-
dex. The former three indicate the degree at which Red
Blood Cells clump together. The rigidity index repre-
sents the variability of RBC clumps. The higher the in-
dices, the lower the variability.
CD62p level indicates the active state of platelets.
Statistical analysis
SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) was
used in performing the statistical analyses. Data are ex-
pressed as mean ± standard deviation (SD). Statistical
differences between the two groups were tested using
t-test. Differences were considered statistically signifi-
cant at P<0.05.
RESULTS
The blood sedimentation rate, K value, gather index,
and rigidity index in both groups were improved signif-
icantly (P<0.05) after treatment. However, the four in-
dices in the Jianpi suppository group were more signifi-
cantly decreased (P<0.05) than those in the mesalazine
group (Tables 1, 2). The CD62p level in both
groups was also improved significantly (P<0.05).
However, it was more significantly lowered in the Ji-
anpi suppository group (P<0.05) than in the mesala-
zine group (Table 2).
156
JTCM |www. journaltcm. com April 15, 2014 |Volume 34 | Issue 2 |
Han J et al. / Clinical study
DISCUSSION
UC is associated with hypercoagulability, and particu-
larly, hemorheology and CD62p. UC patients had a
higher blood sedimentation rate, K value, gather index,
and rigidity index before treatment, and their CD62p
level was also significantly higher than that of normal
patients, indicating that their platelet activation is high.
After treatment, a decrease in all tested indices is more
significant in the Jianpi suppository group than in the
mesalazine group. A possible explanation may be that
the Jianpi suppository not only treats symptoms but al-
so regulates the whole body system, while mesalazine
treats and functions only on the target tissues.23
Through our clinical studies, we found that spleen
"damp-heat," which is present in many mild to moder-
ate UC patients, retards blood circulation. Therefore,
blood stasis forms and the invasion of pathogenic wind
and damp damages Yang Qi, resulting in stagnation of
blood circulation. Jianpi suppository promotes blood
circulation and removes blood stasis to treat the root
cause of UC.
The hypercoagulable state is the same as blood stasis in
TCM. Promoting blood circulation to remove blood
stasis is the principle treatment for UC, according to
TCM theory. Jianpi suppository treats UC patients by
regulating Qi activity to reinforce the spleen and pro-
mote blood circulation to repair the erosion of the co-
lon to directly stop diarrhea.
In conclusion, TCM therapy improves the hypercoagu-
lable state of UC patients successfully via significant de-
creases in hemorheology and CD62P indices. More-
over, it is more cost effective than mesalazine. There-
fore, Jianpi suppository can be used clinically for mild
to moderate UC patients, especially in the developing
countries.
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